Clinical Trial Update: Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating symptom benefit rate of trabectedin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Carcinoma

Drugs mentioned

• Trabectedin + PLD

Snippet

Sponsor: AGO Research GmbH | Conditions: Recurrent Ovarian Carcinoma | Phase 3 | Status: TERMINATED